Last reviewed · How we verify
GP plus placebo induction therapy
GP plus placebo induction therapy is a Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development.
GP plus placebo induction therapy is an investigational treatment regimen that combines a primary active agent with placebo in an induction phase to evaluate therapeutic efficacy and safety.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GP plus placebo induction therapy |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This appears to be a clinical trial protocol rather than a defined drug entity. 'GP' likely refers to a specific therapeutic agent (possibly gemcitabine-based or another regimen), combined with placebo control in an induction phase design. The exact mechanism depends on the identity of the 'GP' component, which is not specified in the available information.
Approved indications
Common side effects
Key clinical trials
- Electro-Acupuncture in Lung cancER : EALER Study (NA)
- Effect of an Experimental Cannabidiol Gel on Tooth Sensitivity (PHASE1)
- The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain (NA)
- Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP plus placebo induction therapy CI brief — competitive landscape report
- GP plus placebo induction therapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about GP plus placebo induction therapy
What is GP plus placebo induction therapy?
How does GP plus placebo induction therapy work?
Who makes GP plus placebo induction therapy?
What development phase is GP plus placebo induction therapy in?
Related
- Manufacturer: Sun Yat-sen University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing